RE: Courtesy of pmjh19 Apr 2021 14:09
I disagree Doc. If the arrows are pointing towards likely success with Activ-2 and /or any further data in near-term studies, Wilko et al will be better placed than us to gauge that), then I cannot see why Synairgen would settle for a mediocre offer at this stage. Why throw the towel in when so close to the finish line? Makes no sense and I can't see them quitting ahead of time to pass the baton on. I suspect they will see it through, then do deals, or not.